AdAlta’s IRO Platform Gains Commercial Validation From US$120 Million Deal

Oribiotech Secures Commercial Cell Therapy Commitment

AdAlta Limited (ASX:1AD) has received a useful external endorsement for the manufacturing technology it plans to use in future cellular immunotherapies: Oribiotech has signed a 10-year partnership worth up to US$120 million to integrate its IRO platform into the production of an already approved and commercialised cell therapy.

The undisclosed biopharmaceutical partner is moving an existing commercial manufacturing process onto IRO, rather than testing the system only on an early-stage product. That distinction matters in cell therapy, where manufacturing is closely tied to the product itself and changing equipment or production conditions can require comparability work with regulators.

IRO Offers Scale, Cost and Process Portability

AdAlta says IRO is designed to produce 10 to 50 times more patient doses from the same physical footprint, while potentially reducing manufacturing costs by 30% to 50%. The platform is also intended to automate and digitise labour-intensive steps, reducing variation between batches and making processes easier to transfer between sites.

Those figures are platform claims rather than demonstrated financial outcomes for AdAlta. The company’s strategic argument is that a cellular therapy must be not only clinically effective but also manufacturable at a scale and cost acceptable to a larger pharmaceutical partner.

EW-001 Remains Outside the IRO Strategy

AdAlta’s lead CAR-T therapy, EW-001, will not initially be manufactured on IRO. The company says the asset already has a low-cost, rapid and scalable manufacturing solution, which is being transferred from Shanghai Cell Therapy Group to Australian contract manufacturer Cell Therapies.

That makes the manufacturing strategy more selective than a wholesale platform conversion. AdAlta, Oribiotech and Cell Therapies signed a memorandum of understanding in April 2026 to deploy IRO in Australia and the Asia-Pacific, but deployment for AdAlta will begin only after the company licenses a suitable next product.

Future Pipeline Must Be IRO-Compatible

For products acquired after EW-001, compatibility with IRO is now a design priority. AdAlta says it is prioritising “East to West” candidates whose manufacturing can be built on the platform from the outset, with the aim of entering future partnering discussions using a system that has already been selected for commercial production by another biopharmaceutical company.

The commercial signal is meaningful, but its limits are clear. AdAlta is not a party to the US$120 million agreement, the partner remains unnamed, the headline value is capped at “up to” US$120 million, and the announcement discloses no direct payment, funding or revenue for AdAlta. The next test is whether the company can secure an IRO-compatible asset and move it into development at Cell Therapies.